New Drug Combo Boosts Prostate Cancer Survival by 5%

For men facing high-risk prostate cancer, a new combination therapy is offering real hope where options were once limited.

A groundbreaking international trial involving over 2,100 patients found that adding the drug apalutamide to standard hormone therapy dramatically improved outcomes for men with aggressive prostate cancer. The results were published in The New England Journal of Medicine.

The numbers tell a promising story. Nearly 9 percent of patients who received the combination therapy achieved complete response or minimal remaining disease at surgery, compared to just 1 percent with standard treatment alone. That's a tenfold improvement.

"The drug itself is not going to do the full job, but it's way better than standard hormone therapy alone," said Dr. Ashley Ross, a professor of Urology at Northwestern University who co-authored the study.

The benefits extended beyond surgery day. At five years, 78 percent of patients who received apalutamide remained free of cancer spreading to other parts of their body, compared with 73 percent in the control group.

What makes this approach different is timing. Traditionally, doctors might operate first and add treatments later if cancer returns. This trial tested giving therapy both before and after surgery, treating the cancer more aggressively from the start.

The patients in this study had particularly tough cases. Many showed signs their cancer had already begun spreading locally, putting them at high risk for relapse after surgery.

The Bright Side

This breakthrough doesn't replace existing treatments but adds a third major option for patients and their doctors to consider. Men with high-risk disease can now choose surgery alone, radiation with hormone therapy, or this new combination approach followed by surgery.

Side effects were manageable for most patients. While 40 percent experienced adverse events compared to 31 percent on standard treatment, most issues were rashes that doctors know how to handle effectively.

Dr. Ross emphasized that questions remain about which approach works best for individual patients. Two additional studies are underway, including one comparing this method to surgery without systemic therapy, and another testing the drug combination with radiation instead of surgery.

For thousands of men diagnosed with aggressive prostate cancer each year, having more proven options means more paths to survival.